GlassScriptPhysician profile
Michael A Saidel
NPI 1184780330
$51,410.75
in general payments reported to CMS, 2019-2025
29 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $11K · 2021: $3,207 · 2022: $504 · 2023: $938 · 2024: $8,617 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $7,475 · Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $7,474.85 |
| Food and Beverage | $3,087.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $18,777.10 | 2019-2025 | Cequa |
| Glaukos Corporation | $8,207.89 | 2021-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Photrexa Viscous and Photrexa |
| Eyepoint US, INC. | $8,090.78 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,088.77 | 2019-2021 | |
| Integra Lifesciences Corporation | $3,900.15 | 2019 | |
| Kala Pharmaceuticals, INC. | $1,379.55 | 2020-2021 | |
| Alcon Vision LLC | $1,042.06 | 2019-2025 | Rocklatan, Clareon, Eysuvis |
| Abbvie INC. | $339.31 | 2022-2025 | Durysta, Lumigan |
| Bausch & Lomb Americas INC. | $301.83 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $288.99 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $272.43 | 2024-2025 | Iheezo, Vevye |
| Oyster Point Pharma, INC. | $266.53 | 2022-2024 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $246.21 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $201.12 | 2019-2021 | |
| Allergan, INC. | $138.44 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $135.63 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $111.55 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $97.99 | 2021 | |
| Sight Sciences, INC. | $83.58 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Astellas Pharma US INC | $76.70 | 2023-2024 | Izervay |
| Carl Zeiss Meditec, INC. | $74.79 | 2019-2020 | |
| Thea Pharma INC. | $72.87 | 2023-2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $45.82 | 2022 | |
| Rayner Intraocular Lenses Limited | $42.94 | 2024-2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Beaver-Visitec International, INC. | $25.36 | 2023 | |
| Ocular Therapeutix, INC. | $16.78 | 2021 | |
| Amgen INC. | $15.08 | 2025 | Tepezza |
| New World Medical,INC. | $12.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.